In recent years, there has been an ongoing effort to enhance productivity in drug discovery through various technological advances such as high-throughput screening ¤HTS¥ and combinatorial chemistry. To keep up with these evolving technologies, discovery drug metabolism and pharmacokinetics ¤DMPK¥ scientists in industry have improved the throughput and efficiency of DMPK screening, which has provided timely risk analysis of compounds to research project teams.
In many companies, screening systems for permeability, metabolic stability, inhibition/induction of CYPs and transporter substrates/inhibitors are currently available for risk analyses. Thus, most significant DMPK properties that need to be taken into account for compound selection are currently characterized at the discovery stage. In addition, DMPK support using interpretation capabilities, e.g., quantitative human PK prediction, pharmacokinetic/pharmacodynamic ¤PK/PD¥ analysis and metabolite profiling makes DMPK an integral part of drug discovery. However, despite all these endeavors, the number of new chemical entities launched on the market tends to decrease. Although there are various factors that affect this tendency, the drug discovery process could certainly be a contributing factor and should therefore be carefully reviewed and further optimized.
Under these circumstances, discovery DMPK scientists should deliberate whether the current practices of DMPK research are sufficient to overcome the stagnation and should ask themselves the following questions:
-Are we well differentiated from contact research organizations ¤CROs¥ with respect to screening technologies and risk analysis capabilities? -Do we make flexible decisions based on DMPK data and criteria, considering the positions of respective research projects, not just automatically killing compounds? -Do we provide solutions to problems and add value to research projects? -Do we take the initiative in the determination of the direction of research projects?
In order to confidently say úyesû to all of these questions, DMPK scientists are required not only to improve their core capabilities, but also to deepen their knowledge of multiple research areas that form an interface with DMPK ¤Fig. 1¥. These boundary research areas comprise all drug discovery functions including HTS, physicochemistry/formulation, pharmacology, toxicology and chemistry. One may think that the boundary research areas have already been more or less supported by DMPK functions such as PK/PD analysis. Here, the question that should be emphasized is whether every DMPK scientist who is assigned as a research project DMPK representative is capable of proactively and objectively proposing case-by-case solutions to any problems that may arise in both the core DMPK and boundary research areas.
For improvement of core DMPK technologies, further efforts to implement quantitative human PK and drugdrug interactions ¤DDI¥ prediction are indispensable. Many researchers have reported successful prediction using in vitro®in vivo extrapolation of CYP-mediated hepatic clearance and DDI in a quantitative manner. But further data accumulation is required for the quantitative prediction of the impact of CYPs in other organs, as well as the impact of other enzymes and transporters. Prediction of human PK and DDI incorporating individual variability and the effect of disease states and change in physiological conditions may DMPK scientists that are involved in research project teams have the potential to impact many different functional areas. For example, at the boundary between DMPK and HTS, DMPK scientists may be involved in interpretation of discrepancies in inhibition activity of compounds between enzyme and cell, and in understanding the relationship between compound reactivity and biological activity.
At the boundary between DMPK and physicochemistry/ formulation, DMPK scientists should help the team to understand the effects of salt/cocrystal, crystal polymorphism, micronization, solid dispersion and DDS formulation on absorption and make appropriate recommendations.
At the DMPK/pharmacology interface, DMPK scientists should understand the mechanism of action of each target in detail, identify desired PK profiles and investigate whether compounds exhibit target-specific pharmacodynamic effects using correlation analysis between PK results and PD data, which may include imaging data. Taking all of this information into account, they could also discuss PD characterization and propose changes to pharmacology study design such as optimized sampling points based on the result of modeling and simulation. In addition, they could further contribute by establishing bioanalytical methods for PD markers, making use of their fundamental skills.
At the DMPK/toxicology interface, DMPK scientists should not only detect reactive metabolites but also interpret their association with toxicity through mechanistic analysis, considering the effect of the immune system and the relevance to mitochondorial toxicity and oxidative stress. Toxicokinetic/toxicodynamic ¤TK/TD¥ analysis, which is currently performed less often than PK/PD analysis, will be further expedited by DMPK scientistsö initiatives.
At the DMPK/chemistry interface, structure-DMPK property relationship analysis should be implemented to aid in chemical modification of each series of compounds. It would also be their responsibility to develop knowledgebased tools using accumulated in-house data to relate characteristics of respective moieties to DMPK properties.
It should be noted that the above-mentioned research activities could become unnecessary once the knowledge to solve problems is shared among projects and scientists from other discipline areas take on these roles. Hence, DMPK scientists should continue to improve their skills in all of the boundary research areas as well as their core DMPK function as generalists of drug discovery. If they become scientists with multidisciplinary competencies, they will be recognized as key drivers to boost productivity in research projects. To aid in this effort, the Japanese Society for the Study of Xenobiotics ¤JSSX¥ offers a range of topics across several disciplines that are of interest to discovery DMPK scientists, continuously supporting their efforts to become scientists who generate great value in industry. Toshiya MORIWAKI, Ph.D.
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